Stock Price of Orexigen Therapeutics, Inc. (OREX) Increases 22.75%

Stock price performance of Orexigen Therapeutics, Inc. is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 62.06% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -4.65% . Looking at the past 52 week period, the stock price is down -77.72% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Orexigen Therapeutics, Inc. has a negative value of -69.08 compared to overall market performance. Company shares have received an average consensus rating of Hold for the current week The stock has recorded a 20-day Moving Average of 10.03% and the 50-Day Moving Average is 37.34%.The 200 Day SMA reached 3.45%

Based on the Stock Research Orexigen Therapeutics, Inc. Relative Strength Index signal is in over bought territory with a range of 73.05. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has climbed 22.75% in the past week and advanced 21.3% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 22.61% and the outperformance has advanced to 20.22% for the last 4 weeks period.

Company has reported several Insider transactions to the SEC, on Dec 21, 2016, Stephen A. Moglia (VP, Chief Accounting Officer) sold 800 shares at 1.96 per share price.On Mar 2, 2015, Mark D Booth (Chief Commercial Officer) sold 50,000 shares at 5.68 per share price.

Orexigen Therapeutics Last issued its quarterly earnings results on Nov 3, 2016. The company reported $1.12 EPS for the quarter, beating the analyst consensus estimate by $ 3.44. Analyst had a consensus of $-2.32. The company had revenue of $7.00 million for the quarter, compared to analysts expectations of $11.90 million. The companys revenue was down -29.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.09 EPS.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) : On Friday heightened volatility was witnessed in Orexigen Therapeutics, Inc. (NASDAQ:OREX) which led to swings in the share price. The stock opened for trading at $3.58 and hit $4.3 on the upside , eventually ending the session at $4.1, with a gain of 15.82% or 0.56 points. The heightened volatility saw the trading volume jump to 2,657,318 shares. The 52-week high of the share price is $19.25 and the company has a market cap of $60 million. The 52-week low of the share price is at $1.65 .

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Companys lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Companys understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.


Share this post

Leave a Reply